R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways
- PMID: 14985458
R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways
Abstract
Ras activation is frequently observed in multiple myeloma either by mutation or through interleukin-6 receptor signaling. Recently, drugs designed to inhibit Ras have shown promise in preclinical myeloma models and in clinical trials. In this report, we characterize the pathways by which the clinically tested farnesyl transferase inhibitor (FTI) R115777 induces apoptosis in multiple myeloma cells. Contrary to the proposed mechanistic action of FTIs, we found that R115777 induces cell death despite Ras prenylation implying participation of Ras-independent mechanism(s). Apoptosis proceeded via an intrinsic cascade and was associated with an increase in the expression and activity of Bax. Bax activation correlated with a loss of mitochondrial membrane integrity and activation of the endoplasmic reticulum (ER) stress response. These pathways activate caspase-9 and consistent with this, cell death was prevented by caspase-9 blockade. Interestingly, cells overexpressing Bcl-X(L) remained partially sensitive to R115777 despite suppression of mitochondrial membrane dysfunction and ER-related stress. Taken together, these results indicate that R115777 induces apoptosis in a Ras-independent fashion via multiple intrinsic pathways.
Similar articles
-
Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells.Leuk Lymphoma. 2003 Dec;44(12):2123-34. doi: 10.1080/1042819031000116652. Leuk Lymphoma. 2003. PMID: 14959858
-
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.Clin Cancer Res. 2005 Aug 15;11(16):6057-64. doi: 10.1158/1078-0432.CCR-04-2685. Clin Cancer Res. 2005. PMID: 16115951
-
Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells.Leukemia. 2002 Sep;16(9):1664-7. doi: 10.1038/sj.leu.2402629. Leukemia. 2002. PMID: 12200678
-
Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discovery.Mol Cancer Ther. 2002 Dec;1(14):1361-5. Mol Cancer Ther. 2002. PMID: 12516971 Review.
-
Ras proteins: recent advances and new functions.Blood. 1999 Nov 1;94(9):2971-80. Blood. 1999. PMID: 10556179 Review. No abstract available.
Cited by
-
Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels.J Pharmacol Exp Ther. 2011 Jun;337(3):636-43. doi: 10.1124/jpet.110.172809. Epub 2011 Mar 4. J Pharmacol Exp Ther. 2011. PMID: 21378206 Free PMC article.
-
Bone marrow microenvironment and the identification of new targets for myeloma therapy.Leukemia. 2009 Jan;23(1):10-24. doi: 10.1038/leu.2008.259. Epub 2008 Oct 9. Leukemia. 2009. PMID: 18843284 Free PMC article. Review.
-
Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies.Int J Mol Sci. 2022 Mar 28;23(7):3706. doi: 10.3390/ijms23073706. Int J Mol Sci. 2022. PMID: 35409064 Free PMC article. Review.
-
Targeting the Isoprenoid Biosynthetic Pathway in Multiple Myeloma.Int J Mol Sci. 2022 Dec 21;24(1):111. doi: 10.3390/ijms24010111. Int J Mol Sci. 2022. PMID: 36613550 Free PMC article. Review.
-
Emerging therapies for multiple myeloma.Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278. Expert Opin Emerg Drugs. 2009. PMID: 19249983 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials